Tuesday, May 30, 2023


Biotechnology News Magazine

STERIS Announces Leadership Succession Plan

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

February 3, 2021

STERIS plc today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS’s leadership and Board for the next two years.

STERIS’s Board of Directors has unanimously appointed Dan Carestio, currently Chief Operating Officer (COO), to the Board of Directors as of January 29, 2021 and Mr. Carestio will succeed Mr. Rosebrough as President and CEO, effective July 29, 2021.  The board intends to include Mr. Carestio on the slate of Directors for election at the upcoming Annual General Meeting, and Mr. Rosebrough has advised the Board that he does not intend to stand for re-election.

“I believe that STERIS is stronger and better positioned than ever and has a very talented overall leadership team in place to continue to drive forward,” said Walt Rosebrough, President and CEO.  “Dan has been with STERIS over twenty years with progressively increasing responsibilities in marketing, sales, and general management.  He drove our improvements in Life Sciences and Applied Sterilization Technologies (AST) segments the past decade”

Rosenbrough added, “He led the successful integration of the Synergy Health AST business, took on the additional leadership of our Healthcare IPT business when that leader retired, and finally became responsible for all our operations as COO in 2018.  The success of all three of our business segments since he became COO is a testament to Dan and the STERIS leadership team.  I am extremely confident that Dan is the right person to lead STERIS into the future.”

“This announcement follows a well-planned and thoughtful succession process, which prioritizes developing leaders from within the Company,” said Dr. Mohsen Sohi, Chairman of the Board. “Dan has a long history of demonstrating his ability to lead and drive results, and the Board has full confidence in him as the next CEO for STERIS.  We are fortunate to have had Walt’s leadership for well over a decade, through some of the most challenging times in STERIS’s history.

Sohi concluded, “During Walt’s tenure, we have grown revenue three-fold, completed close to fifty acquisitions, added more than 8,000 people to our workforce and grown shareholder value nearly 10 times, adding over $14 billion of market capitalization.  We are forever grateful for his contributions and look forward to continuing to have access to his counsel and expertise as an advisor to the Board and senior management for the next two years.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine